IMVT

Rating neutralAI MemoPost-earnings T+3

Immunovant

As of 2026-05-23/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-23 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q4/FY26 earnings release was overshadowed by IMVT-1402 RA data • 2026-05-20

Expected move: +11%

Biggest risk

The bear case remains that batoclimab is being discontinued, FY26 R&D spend rose to $456.7 million, net loss widened to $505.6 million, and the lead asset still needs to prove itself in blinded/registrational settings before the market should assign durable value. Even with a $902.1 million cash balance, the company is still a capital-intensive, single-asset-heavy biotech with substantial execution risk.

Invalidation

Break below $18 or thesis failure.

What would change my mind?

The post-print bull case is that the market is willing to look through the widened loss because IMVT-1402 produced strong open-label D2T RA activity, no new safety signals, and enough cash to fund announced indications through a potential GD launch. Stifel was reported to reiterate Buy with a $49 target after the release, reinforcing that some analysts see the data as supporting a higher valuation.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-23

Base target

$37

p=50%

Bull target

$52

p=25%

Bear target

$18

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

IMVT-1402 D2T RA and CLE updates in 2H 2026 remain the next re-rating test
Graves' disease and other potentially registrational programs are the longer-dated valuation driver
The post-print bull case is that the market is willing to look through the widened loss because IMVT-1402 produced strong open-label D2T RA activity, no new safety signals, and enough cash to fund announced indications through a potential GD launch.

BearKey bullets

Batoclimab discontinuation leaves IMVT-1402 as the dominant strategic driver, increasing concentration risk.
FY26 operating burn rose sharply, with R&D up to $456.7 million and net loss to $505.6 million, so future capital needs remain a risk despite the current cash runway.
Management's longer-dated indication set (GD, MG, CIDP, SjD) faces normal clinical, regulatory, and timing risk, and the company itself warns that early results may not predict later outcomes.

WatchKey bullets

Q4/FY26 earnings release was overshadowed by IMVT-1402 RA data

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $37 (p=50%)

Bull/Bear spread: +56% / -46%

Vs latest close: Bull +56% · Base +11% · Bear -46%

Scenario probabilities

Bull Target: $52 (p=25%)Base Target: $37 (p=50%)Bear Target: $18 (p=25%)

Commentary

The post-earnings reaction was driven more by IMVT-1402 rheumatoid-arthritis data than by the wider fiscal Q4 loss; coverage cited an 8.41% pre-market gain and framed the earnings miss as secondary. Analyst follow-through was only partial, with Stifel reportedly reiterating Buy/$49, while broader revision coverage was still sparse. This remains a monitoring-style biopharma name rather than a clean post-print rerate because the main value driver is still a program-specific clinical readout path, not operating leverage.

As of 2026-05-23 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

IMVT-1402 D2T RA and CLE updates in 2H 2026 remain the next re-rating test
Graves' disease and other potentially registrational programs are the longer-dated valuation driver

Scenarios

Bull Target (Scenario probability)

$52 / p=25% prob

Base Target (Scenario probability)

$37 / p=50% prob

Bear Target (Scenario probability)

$18 / p=25% prob

Price $33 as of 2026-05-29

Nearest Scenario: Base (∆ 11%)

Targets vs latest close: Bull +56% · Base +11% · Bear -46%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-20
Q4/FY26 earnings release was overshadowed by IMVT-1402 RA data
On May 20, 2026, Immunovant reported a fiscal fourth-quarter net loss of $147.9 million ($0.73/share) and FY26 net loss of $505.6 million ($2.77/share), but the release also highlighted IMVT-1402 Week 16 D2T RA ACR20/50/70 response rates of 72.7%/54.5%/35.8%, no new drug-related safety signals, and $902.1 million in cash; batoclimab was discontinued and management said other clinical timelines remain on track [#8-K-2026-05-20].
Prob 95.00% • Move 10.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

IMVT-1402 D2T RA and CLE updates in 2H 2026 remain the next re-rating test
2026-10-31
Management said the D2T RA study remains ongoing, with further updates and topline data from the fully enrolled CLE proof-of-concept trial expected in 2H 2026; this is the next meaningful readout set that can confirm whether the open-label RA signal translates beyond the initial period [#8-K-2026-05-20].
Prob 70% • Move 18% • Priced-in 40%
Graves' disease and other potentially registrational programs are the longer-dated valuation driver
2027-06-30
The company said other clinical development timelines remain on track for IMVT-1402, including potentially registrational trials in Graves' disease, myasthenia gravis, CIDP and SjD; coupled with the stated runway through potential commercial launch in GD, these programs are the main medium-term valuation support [#8-K-2026-05-20].
Prob 60% • Move 25% • Priced-in 25%

Risks

Batoclimab discontinuation leaves IMVT-1402 as the dominant strategic driver, increasing concentration risk.
FY26 operating burn rose sharply, with R&D up to $456.7 million and net loss to $505.6 million, so future capital needs remain a risk despite the current cash runway.
Management's longer-dated indication set (GD, MG, CIDP, SjD) faces normal clinical, regulatory, and timing risk, and the company itself warns that early results may not predict later outcomes.
The D2T RA results are open-label and early-stage; they still need confirmation in blinded and potentially registrational settings.

Peers

Symbol	Summary
CELC	Closest size-and-stage comp: a mid-cap clinical biotech where valuation is primarily driven by program data readouts, safety, and trial execution rather than current earnings power.
PCVX	Another similar-cap biotech comp that trades on pipeline milestones and cash runway; useful as a readout-driven peer, though its product mix is less directly comparable.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-23

AI Stock Memo: IMVT - Immunovant - RankAlpha